RestorGenex To Present Glioblastoma Data At Keystone Conference On PI 3-Kinase Signaling Pathways In Disease Conference

RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that David Sherris, Ph.D., chief scientific officer of RestorGenex, will present scientific data on the Company’s proprietary RES-529 program in oncology, focusing on glioblastoma multiforme entitled, “Validation of RES-529, a novel TORC1/TORC2 allosteric dissociative PI3K inhibitor in glioblastoma multiforme.” Dr. Sherris’s poster presentation at the Keystone Conference on PI 3-Kinase Signaling Pathways in Disease is scheduled for Friday, January 16, 2015 from 12:00 PM - 2:30 PM (PST) at the Fairmont Hotel Vancouver, Vancouver, British Columbia.

Help employers find you! Check out all the jobs and post your resume.